Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions
Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative bioavailability of moexipril HCl/
hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals
USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking
subjects under non-fasting conditions.